Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons ...

New Zealand Nurses Organisation Tōpūtanga Tapuhi Kaitiaki o Aotearoa (NZNO) has deep concerns about the humanitarian crisis in Gaza and the aggression of the Israeli state towards the Palestinian ...

Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts ...

Corcept is a profitable biotech company with significant potential for growth, focusing on treating Cushing's Syndrome and ...

Cigna said Boehringer Ingelheim's Cyltezo, Simlandi from Teva and Alvotech ... they have a role in lowering drug costs and that only drugmakers can set the list prices for their medicines.

Aside from Glenmark’s role in the case, Teva last summer confessed that one of its former employees conspired with competitors to hold off on contract bids and sales of certain drugs three times ...

Rather than waiting for all the patents to expire, they can seek approval for a truncated list of ... found that Teva's label for its generic encouraged doctors to use the drug to treat heart ...